A second Phase III study of Auris Medical Holding AG's investigational product, Keyzilen (esketamine, AM-101), has failed to improve acute inner ear tinnitus in a top-line interim analysis, adding to other negative trial results reported by the neurotology specialty company.
Auris Medical's Second Phase III Tinnitus Trial Disappoints
Auris Medical Holding's investigational tinnitus product, Keyzilen, has failed to meet its primary efficacy endpoint in an interim analysis of a second Phase III trial, adding to a series of clinical disappointments over the past few years for the Swiss biotech.
